The role of neutrophils in neuroblastoma has also been evidenced clinically with superior responses to anti-GD2 antibody therapy obtained following the addition of GM-CSF to the treatment regimen, and was further enhanced in patients who possessed a polymorphic variant of FcγRIIa67,68. This evidence concerns the gene CSF2 and neuroblastoma.